Prolonged survival in a patient with BRCA2 associated metastatic pancreatic cancer after exposure to camptothecin: A case report and review of literature

Anti-Cancer Drugs

Volumn 20, Issue 7, 2009, Pages 634-638

  James, Edward ^a   Waldron Lynch, Maeve G ^b   Saif, Muhammad Wasif ^b  

^a HOSPITAL OF SAINT RAPHAEL   (United States)

^b YALE UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

BRCA1; BRCA2; Breast cancer; Camptothecin; Mitomycin C; Pancreatic cancer; Topoisomerase I; Topoisomerase I inhibitor

Indexed keywords

BRCA2 PROTEIN; CAMPTOTHECIN; CAPECITABINE; CETUXIMAB; DOCETAXEL; GEMCITABINE; IRINOTECAN; MITOMYCIN C; OXALIPLATIN; ANTINEOPLASTIC AGENT; DRUG DERIVATIVE;

AGED; ARTICLE; CANCER RISK; CANCER SURVIVAL; CASE REPORT; DRUG WITHDRAWAL; FAMILY HISTORY; GENE MUTATION; HUMAN; HYPERSENSITIVITY REACTION; MALE; MULTIPLE CYCLE TREATMENT; PANCREAS CANCER; PANCREAS CARCINOMA; PRIORITY JOURNAL; PROSTATE CARCINOMA; TUMOR SUPPRESSOR GENE; DRUG RESISTANCE; GENETIC PREDISPOSITION; GENETICS; METASTASIS; PANCREAS TUMOR; PATHOLOGY; REVIEW; SURVIVAL RATE;

AGED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CAMPTOTHECIN; DRUG RESISTANCE, NEOPLASM; GENES, BRCA2; GENETIC PREDISPOSITION TO DISEASE; HUMANS; MALE; NEOPLASM METASTASIS; PANCREATIC NEOPLASMS; SURVIVAL RATE;

EID: 70149107010     PISSN: 09594973     EISSN: None     Source Type: Journal    
DOI: 10.1097/CAD.0b013e32832b511e     Document Type: Article

References (31)

1. Tulinius H, Egilsson V, Olafsdóttir GH, Sigvaldason H. Risk of prostate, ovarian and endometrial cancer among relatives of women with breast cancer. BMJ 1992; 305:855-857.
2. Phelan CM, Lancaster JM, Tonin P, Gumbs C, Cochran C, Carter R, et al. Mutation analysis of the BRCA2 gene in 49 site-specific breast cancer families. Nat Genet 1996; 13:120-122. (Pubitemid 126528242)
3. Cancer risks in BRCA2 mutation carriers. The breast cancer linkage consortium. J Natl Cancer Inst 1999; 91:1310-1316.
4. Van der Heijden MS, Brody JR, Dezentje DA, Gallmeier E, Cunningham SC, Swartz MJ, et al. In vivo therapeutic responses contingent on Fanconi anemia/ BRCA2 status of the tumor. Clin Cancer Res 2005; 11:7508-7515.
5. Van der Heijden MS, Brody JR, Gallmeier E, Cunningham SC, Dezentje DA, Shen D, et al. Functional defects in the fanconi anemia pathway in pancreatic cancer cells. Am J Pathol 2004; 165:651-657.
6. Rahden-Staroñ I, Szumiło M, Grosicka E, Kraakman van der Zwet M, Zdzienicka MZ. Defective BRCA2 influences topoisomerase I activity in mammalian cells. Acta Biochim Pol 2003; 50:139-144.
7. Burris HA, Moore MJ, Andersen J, Green MR, Rothenberg ML, Modiano MR, et al. Improvements in survival and clinical benefit with gemcitabine as first line therapy for patients with advanced pancreas cancer: a randomised trail. J Clin Oncol 1997; 15:2403-2413.
8. Moore MJ, Goldstein D, Hamm J, Figer A, Hecht JR, Gallinger S, et al. Erlotinib plus gemcitabine compared with gemcitabine alone in patients with advanced pancreatic cancer: a phase III trial of the National Cancer Institute of Canada Clinical Trials Group. J Clin Oncol 2007; 25: 1960-1966.
9. Kang SP, Saif MW. Optimal second line treatment options for gemcitabine refractory advanced pancreatic cancer patients. Can we establish standard of care with available data? JOP 2008; 9:83-90.
10. Thull DL, Vogel VG. Recognition and management of hereditary breast cancer syndromes. Oncologist 2004; 9:13-24.
11. Tavtigian SV, Simard J, Rommens J, Couch F, Shattuck-Eidens D, Neuhausen S, et al. The complete BRCA2 gene mutations in chromosome 13q-linked kindreds. Nat Genet 1996; 12:333-337.
12. Venkitaraman AR. Cancer susceptibility and the functions of BRCA1 and BRCA2. Cell 2002; 108:171-182.
13. Marmorstein LY, Ouchi T, Aaronson SA. The BRCA2 gene product functionally interacts with p53 and RAD51. Proc Natl Acad Sci USA 1998; 95:13869-13874.
14. Marston NJ, Richards WJ, Hughes D, Bertwistle D, Marshall CJ, Ashworth A. Interaction between the product of the breast cancer susceptibility gene BRCA2 and DSS1, a protein functionally conserved from yeast to mammals. Mol Cell Biol 1999; 19:4533-4542.
15. Liu J, Yuan Y, Huan J, Shen Z. Inhibition of breast and brain cancer cell growth by BCCIPalpha, an evolutionarily conserved nuclear protein that interacts with BRCA2. Oncogene 2001; 20:336-345.
16. Fine RL, Fogelman DR, Schreibman SM, Desai M, Sherman W, Strauss J, et al. The gemcitabine, docetaxel and capecitabine (GTX) regimen for metastatic prostate cancer: a retrospective analysis. Cancer Chemother Pharmacol 2008; 61:167-175.
17. Karpetis CS, Khambata-Ford S, Jonker DJ, O'Callaghan CJ, Tu D, Tebbutt NC, et al. K-ras mutations and benefit from cetuximab in advanced colorectal cancer. N Engl J Med 2008; 359:1757-1765.
18. Goggins M. Molecular markers of early pancreatic cancer. J Clin Oncol 2005; 23:4524-4530.
19. McKenna S, Eatock M. The medical management of pancreatic cancer: a review. Oncologist 2003; 8:149-160.
20. Chua YJ, Zaclberg JR. Pancreatic cancer is the wall crumbling? Ann Oncol 2008; 19:1224-1230.
21. Goggins M, Canto M, Hruban R. Can we screen high risk individuals to detect early pancreatic carcinoma? J Surg Oncol 2000; 74:243-248.
22. Wang W, Chen S, Brune KA, Hruban R, Parmigiani G, Klein AP. Panc PRO: risk assessment for individuals with a family history of pancreatic cancer. J Clin Oncol 2007; 25:1417-1422.
23. Goggins M, Shutte M, Lu J, Moskaluk CA, Weinstein CL, Petersen GM, et al. Germline BRCA2 gene mutations in patients with apparently sporadic pancreatic carcinomas. Cancer Res 1996; 56:5360-5364.
24. The Breast Cancer Linkage Consortium. Cancer risks in BRCA2 carriers. J Natl Cancer Inst 1999; 91:1310-1316.
25. Hahn SA, Greenhalf B, Ellis I, Sina-Frey M, Rieder H, Korte B, et al. BRCA2 germline mutations in familial pancreatic carcinoma. J Natl Cancer Inst 2003; 95:214-221.
26. Verhoog LC, Brekelmans CTM, Seynaeve C, Dahmen G, van Geel AN, Bartels CC, et al. Survival in hereditary breast cancer associated with germline mutations of BRCA2. J Clin Oncol 1999; 17:3396-3402.
27. Rennert G, Bisland-Naggan S, Barnett-Griness O. Clinical outcomes of breast cancer in carriers of BRCA1 and BRCA2 mutations. N Engl J Med 2007; 357:115-123. (Pubitemid 47057729)
28. Saif MW, Kim R. The role of platinum agents in the management of advanced pancreatic cancer. Expert Opin Pharmacother 2007; 8:2719-2727.
29. Heinemann V, Boeck S, Hinke A, Hinke A, Labianca R, Louvet C. Meta-analysis of randomized trials: evaluation of benefit from gemcitabine-based combination chemotherapy applied in advanced pancreatic cancer. BMC Cancer 2008; 8:82.
30. Scheithauer W, Kornek GV, Brugger S, Ullrich-Pur H, Valencak J, Raderer M, et al. Randomized phase II study of irinotecan plus mitomycin C vs. oxaliplatin plus mitomycin C in patients with advanced fluoropyrimidine/ leucovorin-pre-treated colorectal cancer. Cancer Invest 2002; 20:60-68. (Pubitemid 34151060)
31. Chalasani P, Kurtin S, Dragovich T. Response to third line mitomycin C (MMC)-based chemotherapy in a patient with metastatic pancreatic adenocarcinoma carrying germline BRCA2 Mutation. JOP 2008; 9:305-308.